Selective inhibition of PI3Kγ affects survival and proliferation of chronic lymphocytic leukemia B cells

Click to increase image sizeClick to decrease image size

Acknowledgments

The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: Cat#12535 3T3-msCD40L cells, from Dr. Mark Connors.

Disclosure statement

R.Mar. received research funding from Janssen and Gilead and honoraria from Gilead, Janssen, Abbvie, Roche and Shire. M.L received honoraria from Gilead, MSD, Pfizer. R.Maf. has received speaker fee from Abbvie.

Author contributions

R.Maf. conceived the research, coordinated the research, performed the statistical analyses and interpreted the results; R.Maf. and S.F. performed the in vitro experiments; S.F. acquired and analyzed flow cytometric data; C.G.A. performed some experiments during the revision phase of the manuscript; S.B performed molecular analyses; G.D. and P.Z. managed the biological samples; R.Maf supervised the work-flow and wrote the manuscript; R.Maf., S.F., L.P., M.L., and R.Mar. revised and approved the final version of the paper.

Additional information

Funding

This work was supported by Associazione Italiana per la Ricerca sul Cancro (AIRC) and Fondazione Cariplo (FC) (TRIDEO 16923 R.M., AIRC IG14376 and IG21436 R.M. FIRC/AIRC Triennal Fellowship 16430 S.F.), and now Fondazione Umberto Veronesi (S.F.); Ricerca Finalizzata Giovani Ricercatori 2011-2012, Ministero della Salute (GR-2011-02349282-R.M.), Italy; PRIN 2015 ZMRFEA_002 (R.M.), MIUR, Italy. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.